Senior Associate, Patent Attorney Southampton
Profile of Antony Latham

I joined D Young & Co in 2012 with a background in life sciences. I enjoy making creative arguments, working at the forefront of innovation and helping our smaller clients to develop their business.

I advise a range of clients on the drafting, prosecution, opposition and defence of patents. In particular, I’ve successfully represented a number of companies in contentious proceedings before the European Patent Office (EPO). My expertise is in the biotechnology and pharmaceuticals industries, with a particular focus on antisense oligonucleotides, antibodies, vaccines and gene editing.

Before I joined D Young & Co, I completed a PhD in endothelial cell biology, focusing on small molecule inhibitors of pro-angiogenic signalling pathways. I’ve published a number of papers in peer-reviewed journals and I’ve presented my research at conferences across the globe.

I enjoy being part of a team of like-minded individuals, all striving to provide the highest level of service to their clients.

Qualifications

  • BA (Hons) in Natural Sciences (Biological), Queens' College, University of Cambridge.
  • Foundation Scholarship for high achievement, University of Cambridge.
  • PhD in Biochemistry and Molecular Biology, University of Leeds.
  • Certificate in Intellectual Property Law, Queen Mary, University of London.
  • Certificate in IP Litigation.
  • Chartered Patent Attorney 2016.
  • European Patent Attorney 2016.

Memberships

  • Chartered Institute of Patent Attorneys (CIPA).
  • European Patent Institute (epi).

Publications

  • Latham AM et al. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis. PLoS One 9: e110997 (2014).
  • Fearnley GW et al. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol. Biol. Cell 25: 2509-21 (2014).
  • Latham AM et al. Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells. Br. J. Pharmacol. 165: 245-59 (2012).
Rising Star 2018/19.
IP Stars (Managing IP)
Rising Star 2019/20.
IP Stars (Managing IP)